Forte, M.; d’Amati, A.; Limongelli, L.; Corsalini, M.; Favia, G.; Ingravallo, G.; Barile, G.; Capodiferro, S.
Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension? Healthcare 2024, 12, 457.
https://doi.org/10.3390/healthcare12040457
AMA Style
Forte M, d’Amati A, Limongelli L, Corsalini M, Favia G, Ingravallo G, Barile G, Capodiferro S.
Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension? Healthcare. 2024; 12(4):457.
https://doi.org/10.3390/healthcare12040457
Chicago/Turabian Style
Forte, Marta, Antonio d’Amati, Luisa Limongelli, Massimo Corsalini, Gianfranco Favia, Giuseppe Ingravallo, Giuseppe Barile, and Saverio Capodiferro.
2024. "Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension?" Healthcare 12, no. 4: 457.
https://doi.org/10.3390/healthcare12040457
APA Style
Forte, M., d’Amati, A., Limongelli, L., Corsalini, M., Favia, G., Ingravallo, G., Barile, G., & Capodiferro, S.
(2024). Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension? Healthcare, 12(4), 457.
https://doi.org/10.3390/healthcare12040457
